GlaxosmithKline’s Lamictal XR–an extended release version of its off-patent Lamictal–has been approved as an add-on therapy for patients 13 years and older with partial seizures. In a 19-week study, Lamictal significantly reduced frequency of seizures compared with the placebo. The drug will be available this summer, the company said in a statement. GSK hopes sales from Lamictal XR will replace the losses incurred when Lamictal went off-patent.
How long before they start shoving it down the throats of people labeled bipolar with arguments of how much better it is then the now generic short action version? It will happen one way or another whether or not it’s done off-label or through some bogus clinical trial. Lamictal has already been shown to be pretty useless in general for bipolar disorder. But we can be sure they will be giving this to psychiatric patients real soon.
And remember extended release varieties of drugs are harder to withdraw from and my withdrawal from regular Lamictal was hell. Oh and let’s not forget it took me two years!